BreathSentry guides patients through correct inhaler technique and measures, in real time, vital signs, execution quality and environmental context — generating Real-World Evidence for asthma and COPD. With no dedicated hardware.
Most respiratory patients use their inhaler incorrectly — and no one notices in time. A correct therapy undermined by the way it is taken.
Three movements, from a single device the patient already owns. No additional sensors, no installation.
The system detects the patient's face, hand, breathing and cough through computer vision and vocal-biomarker analysis during the inhalation act.
A guided pathway leads through each phase of correct technique per ATS/ERS guidelines, including post-inhalation oral hygiene.
Vital signs, execution quality and gesture synchrony are assessed and synthesised into a structured clinical report.
Existing tools tell you whether a patient takes the drug. BreathSentry assesses whether they take it well — and what happens in their body while they do.
Objective assessment of execution accuracy, phase by phase, against international clinical standards.
The key determinant of inhalation efficacy, measured as an objective temporal parameter.
The patient's vital signs during the inhalation act, captured contact-free.
Geolocated air-quality monitoring — humidity, pollen and pollutants — correlated with patient state over time.
Cough analysis through vocal biomarkers, adding an objective acoustic signal layer to the respiratory assessment.
Longitudinal data combining efficacy, technique and context — the evidence clinical research needs.
BreathSentry's multimodal sensing and fusion technology is proprietary and undergoing intellectual-property protection.
A pathway of technological maturation and clinical validation built with scientific rigour.
Complete, working platform, visually validated. TRL 5-6.
Benchmarking against FDA-cleared digital spirometry. Dialogue initiated.
Respiratory risk indicators derived from vital signals. Under research.
A multimodal respiratory digital-biomarker platform.
Inhaler therapy is used by hundreds of millions of patients worldwide. BreathSentry addresses the market through a B2B and B2B2C model.
Real-World Evidence for clinical trials and post-marketing — drug efficacy combined with administration technique.
Remote respiratory coaching and tele-rehabilitation, reducing the burden on in-person care.
Integration into care and adherence programs via partnership, with a patient-facing experience.
A multidisciplinary team with expertise in digital health, AI, respiratory medicine, academic research and European health policy.
Founder & CEO — digital health entrepreneur; registered as an interest representative in the EU Transparency Register, with the Italian Chamber of Deputies and the German Bundestag (digital health / DiGA focus); member of Chatham House.
Full-stack development
Physics — University of Parma
University spin-offs — Real-World Evidence & Real-World Data (RWE & RWD)
Legal & tax structure — London / Dubai
Clinicians and researchers affiliated with the Universities of Bologna, Padua and Parma, with dedicated legal counsel.
For clinical partnerships, research collaborations or platform information.